“Semaglutide versus tirzepatide” sounds like a straightforward comparison between two medicines. In practice, the question often contains several different questions: blood glucose, weight change, cardiovascular events, a particular complication, or the experience of taking a particular product. The answer depends on which question is being asked.
Start with the names. Semaglutide activates the glucagon-like peptide-1 receptor, usually shortened to GLP-1. Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor, or GIP, and the GLP-1 receptor. These descriptions identify pharmacological targets. Counting receptors does not produce a clinical ranking. The ranking, if one is justified, has to come from a comparison of outcomes.
Then separate the active ingredient from the product. A compound name is not a complete prescription label. In the United States, the FDA-approved indication belongs to a specific product and formulation, with a specified population. That distinction has become especially important as labels have changed. The overview here reflects US labeling checked on October 21, 2026.
The same ingredient can have different labels
For injectable semaglutide, Ozempic has indications for glycemic control in adults with type 2 diabetes, for reducing major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and for specified kidney and cardiovascular outcomes in adults with type 2 diabetes and chronic kidney disease. The exact population qualifiers matter; “heart protection” on its own loses information. See the current Ozempic injection label.
Wegovy illustrates why even the brand name can be insufficient. Both its injection and tablet labels include adult weight management in the specified populations and cardiovascular risk reduction in adults with established cardiovascular disease and overweight or obesity. The injection also has an obesity indication for patients aged 12 and older and an accelerated-approval indication for certain adults with noncirrhotic metabolic dysfunction-associated steatohepatitis, or MASH, and moderate to advanced fibrosis. The tablet indications do not simply inherit those additional uses. Accelerated approval also carries a different evidentiary context: confirmation of clinical benefit remains relevant. These distinctions appear in the current Wegovy prescribing information.
Oral semaglutide is no longer accurately summarized by saying “Rybelsus is the tablet.” The current shared US label names Rybelsus and Ozempic tablets, with indications for glycemic control in adults with type 2 diabetes, and reduction of major cardiovascular events in adults with type 2 diabetes at high risk for those events. Readers comparing an older article with a current product listing should check both formulation and revision date. See the Rybelsus/Ozempic tablet label.
Tirzepatide likewise appears under distinct product labels. Mounjaro is indicated for glycemic control in adults and children aged 10 and older with type 2 diabetes. Its August 2026 revision also includes reducing major cardiovascular events in adults with type 2 diabetes at high risk for those events. That is a meaningful change from older summaries of the medicine. See the current Mounjaro label.
Zepbound, also tirzepatide, has adult weight-management indications for the specified obesity or overweight populations and an indication for moderate to severe obstructive sleep apnea in adults with obesity. Those are distinct clinical uses, even though the ingredient is shared with Mounjaro. The Zepbound label supplies the boundaries.
What a direct comparison can establish
The SURMOUNT-5 trial helps answer a narrower, useful question. Researchers randomized 751 adults with obesity, without type 2 diabetes, to injectable tirzepatide or injectable semaglutide in an open-label study. At 72 weeks, estimated mean body-weight change was −20.2% with tirzepatide and −13.7% with semaglutide under the trial's regimens and analysis. Gastrointestinal adverse events were common in both groups. The original trial publication provides the design and results.
That is evidence of a larger average weight reduction with tirzepatide in this comparison. It is not a promise about an individual, a comparison of every available formulation, or a demonstration that every possible health outcome favors the same treatment. A weight endpoint cannot be relabeled as a cardiovascular endpoint. Participants without diabetes cannot silently become a population with diabetes.
The difference between those two reported weight changes is 6.5 percentage points. Percentages and percentage points are easy to blur in headlines, especially when a relative comparison sounds more dramatic. Preserving the original units is a small editorial habit with a large effect on accuracy.
There is also a difference between asking which drug produced a greater average change and asking which treatment fits a particular person's care. The latter involves their medical history, treatment goals, other medicines, tolerability and the relevant product's full safety information. A league table made from a single endpoint cannot perform that assessment.
For anyone reading the next headline, three details do most of the work: the exact product and route, the study population, and the outcome measured. Keep those details attached to the result. GLP-1 and GIP describe biological targets; a careful clinical comparison describes what happened to people.
A thought worth keeping?
